Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina

Related Videos

Are there specific radiographic findings—cavities, diffuse nodules, or expansion of pulmonary nodules—or other triggers in patients with culture-positive MAC lung disease that indicate a need for initiation of antimicrobial therapy? Video

Are there specific radiographic findings—cavities, diffuse nodules, or expansion of pulmonary nodules—or other triggers in patients with culture-positive MAC lung disease that indicate a need for initiation of antimicrobial therapy?

Given the complexity, increasing recognition/prevalence and suboptimal understanding of MAC lung disease, can you summarize for us the disease burden, epidemiology, risk factors, and unmet needs for this infectious condition? Video

Given the complexity, increasing recognition/prevalence and suboptimal understanding of MAC lung disease, can you summarize for us the disease burden, epidemiology, risk factors, and unmet needs for this infectious condition?

Given the efficacy and need for effective therapies such as amikacin liposome inhalation suspension for MAC lung disease, what clinical strategies do you recommend for optimizing adherence, patient satisfaction, and tolerability for this formulation? Video

Given the efficacy and need for effective therapies such as amikacin liposome inhalation suspension for MAC lung disease, what clinical strategies do you recommend for optimizing adherence, patient satisfaction, and tolerability for this formulation?

How do we optimize the clinical benefit of our current treatment regimens and what strategies do you recommend for making patients more adherent and improving tolerability of medications used for MAC lung disease? Video

How do we optimize the clinical benefit of our current treatment regimens and what strategies do you recommend for making patients more adherent and improving tolerability of medications used for MAC lung disease?

What new advances in treatment—including the availability of amikacin liposome inhalation suspension—and other innovations are positively reshaping our approach to managing MAC lung disease and helping reduce its considerable burden? Video

What new advances in treatment—including the availability of amikacin liposome inhalation suspension—and other innovations are positively reshaping our approach to managing MAC lung disease and helping reduce its considerable burden?

Given your experience with amikacin liposome inhalation suspension in the setting of early severe and/or treatment refractory MAC lung disease, can you discuss the design, efficacy, safety, results, and clinical applications of the CONVERT trial? Video

Given your experience with amikacin liposome inhalation suspension in the setting of early severe and/or treatment refractory MAC lung disease, can you discuss the design, efficacy, safety, results, and clinical applications of the CONVERT trial?

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension? Video

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

What is the evidence that the MOA—tissue penetration, intracellular tropism, concentration in macrophages—of amikacin liposome inhalation suspension translates into improved clinical outcomes in patients with MAC lung disease? Video

What is the evidence that the MOA—tissue penetration, intracellular tropism, concentration in macrophages—of amikacin liposome inhalation suspension translates into improved clinical outcomes in patients with MAC lung disease?

Once you have determined that amikacin is appropriate, what formulation of this antimicrobial do you consider? How do MOA and side effects differ between these options and does the MOA of liposome inhaled suspension confer advantages? Video

Once you have determined that amikacin is appropriate, what formulation of this antimicrobial do you consider? How do MOA and side effects differ between these options and does the MOA of liposome inhaled suspension confer advantages?